

May 5, 2011

Tongjitang Chinese Medicines Company
Termination & Mandatory Exchange for Cash

Tongjitang Chinese Medicines Company has merged with Tonsun International Company Limited. Under the terms of the agreement and plan of merger, each Tongjitang Chinese Medicines Company ordinary share was automatically converted into the right to receive \$1.125 in cash without interest and less any applicable taxes, and each Tongjitang ADS (CUSIP# 89025E103) (each of which represents four ordinary shares) was automatically converted into the right to receive \$4.50 in cash without interest and less any applicable taxes.

BNY Mellon has received payment from the Company's paying agent. Effective today, May 4, 2011, holders of Tongjitang ADSs must surrender their ADR certificates to BNY Mellon on a mandatory basis in order to receive the following:

Payment of Merger

Consideration:

Gross Rate per ADR: \$4.500000
Cancel Fee: \$0.000000
Net Rate per ADR: \$4.500000

Please be advised that the Tongjitang ADR program is terminated effective immediately with payment of these proceeds.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York

Wendy Katz

Vice President

+1 212 815-2267

wendy.katz@bnymellon.com

London

Damon Rowan

Vice President

+44 207 964 6527

damon.rowan@bnymellon.com

Hong Kong

Joe Oakenfold

Vice President

+852 2 840 9717

joe.oakenfold@bnymellon.com

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.